31.10.2019
VALBIOTIS announces the success of its capital increase with maintenance of the DPS for an amount of 7.2 million euros (in French)
Download
10.10.2019
VALBIOTIS launches a share capital increase with Shareholders’ Preferential Subscription Rights (in French)
Download
16.09.2019
VALBIOTIS presents positive results from a study on TOTUM-63, active substance of VALEDIA®, at EASD 2019
Download
02.09.2019
Additional positive results from the Phase IIA clinical study on VALEDIA® in lipid metabolism and arterial hypertension
Download
01.08.2019
Provision of the Registration Document (R 19-030) and Statement of cash position as of June 30, 2019 (in French)
Download
03.07.2019
VALBIOTIS announces positive results from the Phase IIA clinical study of VALEDIA®, now the first product proven effective in people with prediabetes
Download
24.06.2019